

ANIKA THERAPEUTICS INC  
Form 8-K  
December 02, 2013

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

---

Date of Report (Date of earliest event reported): **November 29, 2013**

**Anika Therapeutics, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

**Massachusetts**                      **000-21326**                      **04-3145961**  
(State or Other Jurisdiction of    (Commission File    (I.R.S. Employer Identification No.)  
Incorporation)                      Number)

**32 Wiggins Avenue, Bedford, Massachusetts 01730**  
(Address of Principal Executive Offices)                      (Zip Code)

Registrant's Telephone Number, Including Area Code: **(781) 457-9000**

**No Change Since Last Report**

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



**Item 1.02 Termination of a Material Definitive Agreement**

On November 29, 2013, Anika Therapeutics, Inc. (the “Company”) terminated the Credit Agreement (the “Agreement”) entered into on January 31, 2008 among the Company, as borrower, Anika Securities, Inc., a wholly owned subsidiary of the Company, as guarantor, each of the lenders from time to time party thereto and Bank of America, N.A., as administrative agent (“Bank of America”). In connection with the termination, the Company pre-paid in full its entire outstanding debt under the Agreement plus accrued interests. The outstanding debt pre-paid was \$8,400,000.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ANIKA  
THERAPEUTICS, INC.

December 2, 2013 By: /s/ Sylvia Cheung  
Sylvia Cheung  
*Chief Financial  
Officer*